Amazing how tiny setback make folks forget the huge potential still ahead with OTHER ANDAs !
Also have we already forgotten this (below), do you even understand how much money it saves IPCI on the road ahead ?:
"Administration ("FDA") has reviewed the Company's request for Fast Track designation for its abuse deterrent Rexista(TM) Oxycodone XR (Oxycodone HCl) extended-release tablets development program incorporating its Paradoxical OverDose Resistance Activating System ("PODRAS(TM)") and has concluded that it meets the criteria for Fast Track designation.
Fast Track is a designation assigned by the FDA in response to an applicant's request which meets FDA criteria. The designation mandates the FDA to facilitate the development and expedite the review of drugs intended to treat serious or life threatening conditions and that demonstrate the potential to address unmet medical needs. This could potentially result in accelerated approval for Rexista(TM) Oxycodone XR thereby making it available to patients earlier than would be traditionally possible."
If you are long and use some minimal common investing sense, this setback today is nothing but a great BUYING opportunity.